Endocrine Cancer
Conference Coverage
Diabetes from checkpoint inhibitors probably means lifelong insulin
CHICAGO – In the largest case series to date, almost all patients remained on insulin at a median follow-up of 44 weeks, even after stopping ICIs...
Conference Coverage
New and improved classifiers may sharpen thyroid nodule diagnosis
VICTORIA, B.C. – The tests could improve preoperative assessment, even in histologic subsets that pose diagnostic challenges.
Conference Coverage
Cancer patients with TKI-induced hypothyroidism had better survival rates
When it comes to the adverse effects of tyrosine kinase inhibitors, hypothyroidism appears to have a bright side.
Conference Coverage
Calcitonin-to-CEA ratio predicts medullary thyroid cancer survival
Can a ratio of serum calcitonin to carcinoembryonic antigen predict survival in patients with medullary thyroid cancer?
Conference Coverage
Big changes coming for thyroid cancer staging
How big an impact will new thyroid staging criteria have on the numbers of stage I disease? It’ll be huge.
Conference Coverage
Contralateral nodal thyroid metastases show slow progression
BOSTON – In some thyroid cancers, a small level III contralateral nodal metastasis may be watched safely rather than resected.
Conference Coverage
Revised thyroid Bethesda System resets malignant risks
BOSTON – Revised thyroid cancer cytology system “limits malignancy to cases with features of classic malignant papillary thyroid carcinoma.”
Conference Coverage
VIDEO: Lenvatinib’s real-world thyroid cancer performance matches trial
The median time of progression-free survival was 10 months in the registry and 18 months in the pivotal trial.
Conference Coverage
VIDEO: Less follow-up proposed for low-risk thyroid cancer
BOSTON – Can some patients with good treatment responses safely transition to follow-up monitoring at longer intervals?
From the Journals
USPSTF: No thyroid cancer screening for asymptomatic adults
The harms of screening asymptomatic adults for thyroid cancer outweigh the benefits, according to the U.S. Preventive Services Task Force.
From the Journals
Metformin linked with better survival in RCC patients with diabetes
A meta-analysis of eight studies including 254,329 patients found better survival with metformin use.